KPMA predicted positive list system unlikely successful.

The Pharmaceutical Management Analysis Task Force Team (T/F) of the KPMA said in the 2nd quarter meeting after reviewing the recent pharmaceutical environment changes of the KORUS FTA, the NHI drug pricing policy called "Positive List System" and the industry M&A movement that the future FTA negotiation would give impacts to the industry largely depending on how the government perceived the ind...